Background: The aim of this study is to investigate tubular and glomerular function after visceral leishmaniasis (VL) treatment with pentavalent antimonials. Methods: This is a prospective study including 14 patients with VL diagnosis treated with pentavalent antimonials. Urine acidification and concentration tests were performed. Estimated glomerular filtration rate (eGFR), fractional excretion of sodium (FENa) and potassium (FEK) and free water clearance (CH2O) were measured to assess glomerular and tubular function. Results: The VL group had a significantly lower FEK, serum sodium and plasma osmolality (Posm). No significant differences were found regarding proteinuria, eGFR, FENa or CH2O. Patients in the VL group had lower urinary osmolality (Uosm) before DDAVP use when compared to the control group, as well as a lower U/Posm. The urinary pH before and after CaCl2 load was higher in the VL group. Conclusion: This study shows evidence of reversal of some tubular dysfunction in VL, but other dysfunctions may persist, especially urinary acidification capacity.

Keywords:
Visceral leishmaniasis, Kala-azar, Acute kidney injury, Urinary concentration, DDAVP, Urinary acidification
1.
Camargo LB, Langoni H: Impact of leishmaniasis on public health. J Venom Anim Toxins incl Trop Dis 2006;12:527–548.
2.
Efstratiadis G, Boura E, Giamalis P, et al: Renal involvement in a patient with visceral leishmaniasis. Nephrol Dial Transplant 2006;21:235–236.
3.
Guerin PJ, Olliaro P, Sundar S, et al: Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494–501.
4.
Herwaldt BL: Leishmaniasis. Lancet 1999;354:1191–1199.
5.
Albuquerque PL, Silva Júnior GB, Freire CC, Oliveira SB, Almeida DM, Silva HF, Cavalcante MS, Sousa AQ: Urbanization of visceral leishmaniasis (kala-azar) in Fortaleza, Ceará, Brazil. Rev Panam Salud Pública 2009;26:330–333.
6.
Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S: Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 2005;5:763–774.
7.
Salgado Filho N, Ferreira TMAF, Costa JML: Involvement of the renal function in patients with visceral leishmaniasis (kala-azar). Rev Soc Bras Med Trop 2003;36:217–221.
8.
Oliveira MJ, Silva Júnior GB, Abreu KL, Rocha NA, Garcia AV, Franco LF, Mota RM, Libório AB, Daher EF: Risk factors for acute kidney injury in visceral leishmaniasis (kala-azar). Am J Trop Med Hyg 2010;82:449–453.
9.
Daher EF, Evangelista LF, Silva Júnior GB, et al: Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008;12:329–332.
10.
Oliveira AL, Brustoloni YM, Fernandes TD, Dorval ME, Cunha RV, Bóia MN: Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Trop Doct 2009;39:180–182.
11.
Beltrame A, Arzese A, Camporese A, et al: Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B. J Travel Med 2008;15:358–360.
12.
Navarro M, Bonet J, Bonal J, Romero R: Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. Nefrologia 2006;26:745–746.
13.
Rollino C, Bellis D, Beltrame G, et al: Acute renal failure in leishmaniasis. Nephrol Dial Transplant 2003;18:1950–1951.
14.
Lima Verde FAA, Lima Verde FA, Lima Verde IA, et al: Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study of 50 patients from Brazil. J Nephrol 2007;20:430–436.
15.
Mongensen CE: Prediction of clinical diabetic nephropathy in IDDM patients: alternatives to microalbuminuria. Diabetes 1990;39:761–767.
16.
Tryding N, Sterner G, Berg B, Harris A: Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity. Nephron 1987;45:27–30.
17.
Oster JR, Hotchkiss JL, Carbon M, Farmer M, Vaamonde CA: A short duration renal acidification test using calcium chloride. Nephron 1975;14:281–289.
18.
De Brito T, Hoshino-Shimizu S, Neto VA, Duarte IS, Penna DO: Glomerular involvement in human kala-azar: a light immunofluorescent and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg 1975;24:9–18.
19.
Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001;286:421–426.
20.
Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1–28.
21.
Eknoyan G, McDonald MA, Appel D, Truong LD: Chronic tubulo-interstitial nephritis: correlation between structural and functional findings. Kidney Int 1990;38:736–743.
22.
Feldman BJ, Rosenthal SM, Vargas GA, et al: Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884–1890.
23.
Cogan MG: Tubulointerstitial nephropathies: a pathophysiological approach. West J Med 1980;132:134–140.
24.
Morris RC, Fudenberg HH: Impaired renal acidification in patients with hypergammaglobulinemia. Medicine 1967;46:57–69.
25.
Russo LM, Bakris GL Comper WD: Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002;39:899–919.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.